Roy D. Baynes
Chief Medical Officer; Director · 7 filings · Latest: May 5, 2026
Eikon Therapeutics, Inc.
Natera, Inc.
Travere Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
TVTX | Roy D. Baynes | Director | May 5, 2026 | Sale | $46.65 | 4,500 | $209.9K | 37,500 | |
TVTX | Roy D. Baynes | Director | May 5, 2026 | Option Exercise | $18.27 | 4,500 | $82.2K | 42,000 | |
TVTX | ROY BAYNES | — | May 5, 2026 | Proposed Sale | $46.65 | 4,500 | $209.9K | — | |
TVTX | Roy D. Baynes | Director | May 1, 2026 | Sale | $44.22 | 9,750 | $431.1K | 37,500 | |
TVTX | Roy D. Baynes | Director | May 1, 2026 | Option Exercise | $6.82 | 9,750 | $66.5K | 47,250 | |
TVTX | ROY BAYNES | — | May 1, 2026 | Proposed Sale | $44.22 | 9,750 | $431.1K | — | |
TVTX | Roy D. Baynes | Director | Apr 14, 2026 | Sale | $41.29 | 32,750 | $1.4M | 37,500 | |
TVTX | Roy D. Baynes | Director | Apr 14, 2026 | Option Exercise | $17.60 | 32,750 | $576.3K | 70,250 | |
TVTX | ROY BAYNES | — | Apr 14, 2026 | Proposed Sale | $41.29 | 32,750 | $1.4M | — | |
TVTX | Roy D. Baynes | Director | Apr 6, 2026 | Sale | $33.00 | 10,000 | $330.0K | 37,500 | |
TVTX | Roy D. Baynes | Director | Apr 6, 2026 | Option Exercise | $26.52 | 10,000 | $265.2K | 47,500 | |
TVTX | ROY BAYNES | — | Apr 6, 2026 | Proposed Sale | $33.00 | 10,000 | $330.0K | — | |
NTRA | ROY BAYNES | — | Nov 20, 2025 | Proposed Sale | $223.08 | 7,668 | $1.7M | — | |
NTRA | ROY BAYNES | — | Nov 19, 2025 | Proposed Sale | $215.00 | 5,112 | $1.1M | — | |
TVTX | ROY D BAYNES | — | Feb 6, 2025 | Proposed Sale | $22.00 | 10,000 | $220.0K | — | |
TVTX | ROY D BAYNES | — | Jan 23, 2025 | Proposed Sale | $20.00 | 16,000 | $320.0K | — | |
NTRA | ROY D BAYNES | — | Nov 15, 2024 | Proposed Sale | $146.11 | 37,230 | $5.4M | — |